Vertex Pharmaceuticals
Risk Level:
Summary:
Vertex has not terminated business relationships due to religious or political beliefs, though it vets suppliers according to LGBTQ policies. Vertex does not have viewpoint protections for its employees. Vertex limits donations to faith-based charities while supporting the Equality Act and funding the work of critical race theorist Ibram X. Kendi. For these reasons, Vertex receives a "Medium Risk" rating.
Has denied service to customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Vertex Pharmaceuticals received a score of 95 on the Corporate Equality Index from the Human Rights Campaign (1). Among other requirements, this means Vertex vets suppliers according to LGBTQ policies.
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Vertex’s charitable giving policy states that it “will not consider requests from organizations that discriminate on the basis of race, gender, sexual orientation, marital status, religion, age, national origin, veteran’s status or disability”(1).
Employment policies fail to protect against discrimination based on political affiliation/views and/or religion.
Vertex does not protect employees from viewpoint discrimination (1).
Uses corporate reputation to support ideological causes and/or organizations hostile to freedom of expression.
Vertex signed an open letter in support of the Equality Act (1).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Vertex donated $1.5 million to the Boston Center for Antiracist Research, which is led by Ibram X. Kendi, who is noted for his work in support of critical race theory (1).
Uses corporate political contributions for ideological, non-business purposes.
Vertex has not used political contributions for ideological purposes (1).
All links were last accessed and all information was updated on:
December 22, 2022
Company reports are intended for educational use only. Full Disclaimer